Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + durvalumab + tremelimumab
- Development stage
- Unknown
- Lead developer
- Emory University Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
celecoxib + durvalumab + tremelimumab is an experimental combination therapy being investigated for the treatment of advanced or metastatic hepatocellular carcinoma (HCC). This regimen is the focus of the Phase II RECON study (NCT05741151), led by Emory University. It combines celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, with the immune checkpoint inhibitors durvalumab (an anti-PD-L1 monoclonal antibody) and tremelimumab (an anti-CTLA-4 monoclonal antibody). The rationale for this combination is that COX-2 inhibition by celecoxib may reduce the production of immunosuppressive prostaglandins in the tumor microenvironment, potentially overcoming resistance to the dual checkpoint blockade provided by durvalumab and tremelimumab.
- Brand names
- CelebrexImfinziImjudo
- Other names
- RECON Study combinationRECON regimenCelecoxib plus Durvalumab and Tremelimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on celecoxib + durvalumab + tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + durvalumab + tremelimumab.